<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7094151/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Challenges and Solutions in the Management of Adenoviral Keratoconjunctivitis</p>
 </caption>
 <thead>
  <tr>
   <th rowspan="1" colspan="1" id="0-0-.">Challenges</th>
   <th rowspan="1" colspan="1" id="0-1-.">Potential Solutions</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td rowspan="1" colspan="1">High likelihood of transmission and epidemic spread/burden</td>
   <td rowspan="1" colspan="1">Health education in infected individuals and effective disinfection/prevention protocols</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Persistent HAdV secretion in the tears</td>
   <td rowspan="1" colspan="1">Further research regarding the development of a prophylactic antiviral agent</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Reactivation of persistent latent HAdV in the host</td>
   <td rowspan="1" colspan="1">Prevention of spread, treatment of immunocompromised individuals</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Group D HAdV can cause oculogenital infection</td>
   <td rowspan="1" colspan="1">Appropriate testing for HAdV subtype from urethra and conjunctiva in men</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Duration of symptoms and transmission of EKC</td>
   <td rowspan="1" colspan="1">Antivirals: ganciclovir, cidofovir, PVI irrigation</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Poor bioavailability and high toxicity of cidofovir</td>
   <td rowspan="1" colspan="1">Lipid-linked derivative brincidofovir and potential development of ophthalmic formulation</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Development and/or persistence of SEIs</td>
   <td rowspan="1" colspan="1">Topical corticosteroid therapy</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Side effects of long-term corticosteroid use (ie, elevated IOP and cataract formation)</td>
   <td rowspan="1" colspan="1">Immunotherapy such as topical cyclosporine or tacrolimus</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Corticosteroids prolonging viral shedding</td>
   <td rowspan="1" colspan="1">Combination PVI/dexamethasone ophthalmic solution</td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Conjunctival or corneal scarring</td>
   <td rowspan="1" colspan="1">Pseudomembrane removal, PTK</td>
  </tr>
 </tbody>
</table>
